Inventor · disambiguated record
Leah Sabin
Also filed as: SABIN LEAH
4 granted patents·16 pending applications·3 citations·filing 2018–2025
62Inventor score
Top patents by PatentIndex Score
20 records- 0188US12252520B2Myosin 15 promoters and uses thereofDECIBEL THERAPEUTICS INC·Filed 2021·Granted Mar 18, 2025·2 cites·13 claims
- 0280US11622547B2Genetically modified mouse that expresses human albuminREGENERON PHARMA·Filed 2020·Granted Apr 11, 2023·1 cites·12 claims
- 0374US12317874B2Method of using a genetically modified mouse that expresses human albuminREGENERON PHARMA·Filed 2023·Granted Jun 3, 2025·0 cites·30 claims
- 0466US2023338477A1Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe diseaseREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0565US12410442B2Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systemsDECIBEL THERAPEUTICS INC·Filed 2021·Granted Sep 9, 2025·0 cites·19 claims
- 0664US2025302998A1Vectors and methods for in vivo antibody productionREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0764US2025032642A1Crispr-mediated transgene insertion in neonatal cellsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 0862US2025049896A1Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiencyREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0960US2025304637A1Myosin 15 promoters and uses thereofDECIBEL THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1059US2025127928A1Gjb2 regulatory elements and uses thereofDECIBEL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1159US2025304918A1Viral particles retargeted to skeletal muscleREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1258US2025041455A1Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe diseaseREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1358US2024401079A1Stereocilin promoters and uses thereofDECIBEL THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1456US2023149563A1Compositions and methods for expressing factor ix for hemophilia b therapyREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1554US2024002839A1Crispr sam biosensor cell lines and methods of use thereofDECIBEL THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1650US2025388890A1ASS1 Gene Insertion For The Treatment Of Citrullinemia Type IREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1748US2022241430A1Modified viral particles and uses thereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 1848US2025276092A1Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody responseREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1947US2020140492A1Tropism-Modified Recombinant Viral Particles and Uses Thereof for the Targeted Introduction of Genetic Material into Human CellsREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 2043US2020140491A1Tropism-Modified Recombinant Viral Vectors and Uses Thereof for the Targeted Introduction of Genetic Material into Human CellsREGENERON PHARMA·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Leah Sabin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →